CXCL13 is a chemokine gene that functions as an immune-cell trafficking signal and appears to shape the tumor microenvironment, particularly by linking cd8 t cell infiltration with tertiary lymphoid structure abundance. It was identified as significantly upregulated in breast cancer and described as a key immune-related hub gene, with evidence supporting an oncogenic driver role. In metastatic melanoma, CXCL13 was one of the markers in an 82-gene transcriptomic signature associated with primary resistance to immune checkpoint inhibitors. It also defines a CD4+ T-cell subset reported as pro-metastatic, highlighting its involvement in both anti-tumor immunity and tumor-promoting immune states. Recent studies further connect CXCL13 to sympathetic nerve–immune interactions and to PD-1/PD-L1 blockade efficacy, suggesting it may be a biomarker of immune architecture and treatment response. Overall, the literature places CXCL13 at the intersection of cancer immunology, immune checkpoint resistance, and metastatic progression, with multiple 2026 studies reinforcing its functional relevance.
Cancer
- CXCL13 was identified as a significantly upregulated immune-related hub gene and oncogenic driver in breast cancer. (PMID:41920337)
- A 2026 Mammalian Genome study characterized CXCL9, CXCL13, CCL5, and CD74 as key oncogenic drivers in breast cancer. (PMID:41920337)
- CXCL13 was associated with CD8+ T-cell infiltration and tertiary lymphoid structure abundance in the tumor microenvironment. (PMID:41850182)
- Sympathetic innervation was inversely correlated with CXCL13+ CD8+ T-cell infiltration, linking neural regulation to immune contexture. (PMID:41850182)
Immunotherapy resistance
- CXCL13 was included in an 82-gene transcriptomic signature associated with primary resistance to immune checkpoint inhibitors in metastatic melanoma. (PMID:41913413)
- A 2026 Oncoimmunology study used tumor and immune cell transcriptomics to predict primary resistance, placing CXCL13 among key markers. (PMID:41913413)
- The CXCL13-associated immune program may help stratify patients by likelihood of response to PD-1/PD-L1 blockade. (PMID:41850182)
- Targeting tumor-associated sympathetic nerves was reported to orchestrate tertiary lymphoid structures and enhance PD-1/PD-L1 blockade efficacy, with CXCL13-linked immune infiltration as part of this axis. (PMID:41850182)
Metastasis and immune-cell subsets
- CXCL13 was used as a marker to define a CD4+ T-cell subset described as pro-metastatic. (PMID:42029557)
- In a 2026 Cancer Immunology Research study, NMB+ CXCL13+ CD4+ T cells were implicated in promoting malignancy. (PMID:42029557)
- This subset was linked to neuromedin-B signaling and malignant-cell senescence/malignancy programs. (PMID:42029557)
- The findings expand CXCL13’s role beyond chemotaxis to include pro-tumor immune-cell phenotypes. (PMID:42029557)